Fig. 1: Ven/Aza has limited impact on the T-cell compartment. | Leukemia

Fig. 1: Ven/Aza has limited impact on the T-cell compartment.

From: Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment

Fig. 1

A High dimensional clustering by Cytolution of HD PBMCs (A) left untreated or (B) treated with 25 nM Ven and 1 µM Aza for three days in vitro (n = 3). C Specific lysis of OCI-AML3 cells and (D) T-cell expansion in cytotoxicity assays with WT1-TCB and T cells from Ven/Aza-treated patients during their first cycle of treatment (n = 3 per time point). HD T cells were included as control (n = 3). Dots represent mean ± SEM.

Back to article page